Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11842320 | 0.73 | MAPK1 (0.42) | ADORA2AADORA1MAPK1GSK3AGSK3B | |
| SCHEMBL976118 | 0.71 | METAP2 (0.48) | METAP2METAP1EGLN1MAPK1CCNB2 | |
| SCHEMBL4719448 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1 | |
| SCHEMBL30615128 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1CCNB2CDK1 | |
| Zarzissine SCHEMBL1514280 | 0.71 | NUDT1 (0.50) | METAP2METAP1ADORA2AEGLN1 | |
| SCHEMBL29433971 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1 | |
| SCHEMBL14409054 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1 | |
| SCHEMBL813686 | 0.71 | METAP2 (0.44) | METAP2METAP1ADORA2AADORA1EGLN1 | |
| SCHEMBL18757949 | 0.70 | METAP2 (0.43) | METAP2METAP1EGLN1 | |
| SCHEMBL5399592 | 0.67 | NUDT1 (0.44) | METAP2METAP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105189506-A | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG | 2015-12-23 | — | — | CN | disclosed |
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| EP-2920177-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2006086545-A2 | METHOD TO IDENTIFY NOVEL THERAPEUTICS | DESIMONE ROBERT W (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | CYP11B2, CYP11B1, SLC10A1 | METAP2 599/4885METAP1 409/4885ADORA2A 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.